An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations

被引:103
作者
Caulin, Carlos [1 ]
Nguyen, Thao
Lang, Gene A.
Goepfert, Thea M.
Brinkley, Bill R.
Cai, Wei-Wen
Lozano, Guillermina
Roop, Dennis R.
机构
[1] Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA
[4] Baylor Coll Med, Dept Human Mol Genet, Houston, TX 77030 USA
关键词
D O I
10.1172/JCI31721
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Mutations in ras and p53 are the most prevalent mutations found in human nonmelanoma skin cancers. Although some p53 mutations cause a loss of function, most result in expression of altered forms of p53, which may exhibit gain-of-function properties. Therefore, understanding the consequences of acquiring p53 gain-of-fiinction versus loss-of-function mutations is critical for the generation of effective therapies for tumors harboring p53 mutations. Here we describe an inducible mouse model in which skin tumor formation is initiated by activation of an endogenous K-ras(G12D) allele. Using this model we compared the consequences of activating the p53 gain-of-function mutation p53(R172H) and of deleting the p53 gene. Activation of the p53(R172H) allele resulted in increased skin tumor formation, accelerated tumor progression, and induction of metastasis compared with deletion of p53. Consistent with these observations, the p53(R172H) tumors exhibited aneuploidy associated with centrosome amplification, which may underlie the mechanism by which p53(R172H) exerts its oncogenic properties. These results clearly demonstrate that p53 gain-of-function mutations confer poorer prognosis than loss of p53 during skirt carcinogenesis and have important implications for the future design of therapies for tumors that exhibit p53 gain-of-function mutations.
引用
收藏
页码:1893 / 1901
页数:9
相关论文
共 55 条
[1]   Primary care: Cutaneous squamous-cell carcinoma [J].
Alam, M ;
Ratner, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (13) :975-983
[2]   Keratinocyte carcinoma [J].
Albert, MR ;
Weinstock, MA .
CA-A CANCER JOURNAL FOR CLINICIANS, 2003, 53 (05) :292-302
[3]   SKIN HYPERKERATOSIS AND PAPILLOMA FORMATION IN TRANSGENIC MICE EXPRESSING A RAS ONCOGENE FROM A SUPRABASAL KERATIN PROMOTER [J].
BAILLEUL, B ;
SURANI, MA ;
WHITE, S ;
BARTON, SC ;
BROWN, K ;
BLESSING, M ;
JORCANO, J ;
BALMAIN, A .
CELL, 1990, 62 (04) :697-708
[4]   ONCOGENE ACTIVATION IN CHEMICAL CARCINOGENESIS [J].
BALMAIN, A ;
BROWN, K .
ADVANCES IN CANCER RESEARCH, 1988, 51 :147-182
[5]  
Bolshakov S, 2003, CLIN CANCER RES, V9, P228
[6]   Non-melanoma skin cancer: what drives tumor development and progression? [J].
Boukamp, P .
CARCINOGENESIS, 2005, 26 (10) :1657-1667
[7]   A ROLE FOR SUNLIGHT IN SKIN-CANCER - UV-INDUCED P53 MUTATIONS IN SQUAMOUS-CELL CARCINOMA [J].
BRASH, DE ;
RUDOLPH, JA ;
SIMON, JA ;
LIN, A ;
MCKENNA, GJ ;
BADEN, HP ;
HALPERIN, AJ ;
PONTEN, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (22) :10124-10128
[8]   Managing the centrosome numbers game: from chaos to stability in cancer cell division [J].
Brinkley, BR .
TRENDS IN CELL BIOLOGY, 2001, 11 (01) :18-21
[9]   The malignant capacity of skin tumours induced by expression of a mutant H-ras transgene depends on the cell type targeted [J].
Brown, K ;
Strathdee, D ;
Bryson, S ;
Lambie, W ;
Balmain, A .
CURRENT BIOLOGY, 1998, 8 (09) :516-524
[10]  
BURNS PA, 1991, ONCOGENE, V6, P2363